Financial Performance - The estimated net profit attributable to shareholders for the first half of 2024 is projected to be between 69,500 million and 76,000 million CNY, representing a year-on-year growth of 31% to 43% compared to 53,111.36 million CNY in the same period last year [3]. - The estimated net profit after deducting non-recurring gains and losses is expected to be between 65,800 million and 72,300 million CNY, indicating a year-on-year increase of 34% to 48% from 48,994.43 million CNY last year [3]. - The basic earnings per share is projected to be between 1.08 CNY and 1.18 CNY, compared to 0.8247 CNY per share in the same period last year [3]. - The performance forecast data has not been audited by the accounting firm, and the final financial figures will be disclosed in the 2024 semi-annual report [7]. Business Strategy - The company is implementing the "1238" development strategy, focusing on "growth and quality" to drive business transformation and brand enhancement [5]. - The company aims to strengthen its core business in Ejiao while actively exploring new health supplement markets and promoting traditional Chinese medicine culture [6]. - The company is expanding its product offerings, including the nationwide brand expansion of "Peach Blossom Princess Ejiao Cake" and the gradual increase in sales of "Royal Weichang 1619" for men's health [6].
东阿阿胶(000423) - 2024 Q2 - 季度业绩预告